Lipella provides business update and reports 2022 financial results

Company successfully completes phase 2a clinical trial fourth quarter or full year highlights • appointed douglas johnston as cfo in november 2022 • successfully completed initial public offering, attained nasdaq cm listing • year-end cash balance in excess of $5 million subsequent events • attended biotech showcase announcing successful top line results for lead candidate lp-10 during phase 2a clinical trial • created oral health scientific advisory board to focus on development of lp-310 for oral lichen planus • announced the successful completion of phase 2a clinical trial of lp-10 • dr. jason hafron of the michigan institute of urology will present the phase 2a results at the american urological association annual meeting on april 30 pittsburgh , march 31, 2023 /prnewswire/ -- lipella pharmaceuticals inc. (nasdaq: lipo) ("lipella" or the "company"), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today provided a business update and reported financial results for the year ended december 31, 2022. jonathan kaufman, co-founder and ceo of lipella pharmaceuticals, commented, "last year we focused on developing our corporate profile and scientific mission to address serious diseases with significant unmet need.
LIPO Ratings Summary
LIPO Quant Ranking